Cell viability and the (2',5')oligo(A)-RNase L pathway in human colon carcinoma cells treated with human interferons and double-stranded RNA.
M S
MS
Chapekar
R I
RI
Glazer
D015088:2',5'-Oligoadenylate Synthetase / Q000378:metabolism; D000227:Adenine Nucleotides / Q000378:metabolism*; D002455:Cell Division / Q000187:drug effects; D002460:Cell Line; D002470:Cell Survival / Q000187:drug effects; D003110:Colonic Neoplasms / Q000378:metabolism / Q000473:pathology / Q000628:therapy*; D004722:Endoribonucleases / Q000378:metabolism*; D005095:Exoribonucleases / Q000378:metabolism; D006801:Humans; D007370:Interferon Type I / Q000494:pharmacology; D007371:Interferon-gamma / Q000494:pharmacology; D007372:Interferons / Q000494:pharmacology*; D009843:Oligoribonucleotides / Q000378:metabolism*; D011070:Poly I-C / Q000494:pharmacology; D012334:RNA, Neoplasm / Q000378:metabolism; D014158:Transcription, Genetic / Q000187:drug effects
D000227:Adenine Nucleotides; D007370:Interferon Type I; D009843:Oligoribonucleotides; D012334:RNA, Neoplasm; C023505:2',5'-oligoadenylate; D007371:Interferon-gamma; D007372:Interferons; D015088:2',5'-Oligoadenylate Synthetase; D004722:Endoribonucleases; D005095:Exoribonucleases; C029364:2'-phosphodiesterase; C031956:2-5A-dependent ribonuclease; D011070:Poly I-C